(+/-)-6-Methyl-4-chromanol | 18385-73-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (+/-)-6-Methyl-4-chromanol
• 英文别名: 6-methyl chroman-4-ol；6-methylchroman-4-ol；2H-1-Benzopyran-4-ol, 3,4-dihydro-6-methyl-；6-methyl-3,4-dihydro-2H-chromen-4-ol
• CAS: 18385-73-4
• 化学式: C₁₀H₁₂O₂
• 分子量: 164.204
• InChiKey: IOWHBWAURDUJKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  41-42 °C(Solv: ligroine (8032-32-4))
• 沸点：
  282.1±29.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-6-Methyl-4-chromanol 在 2,2'-联吡啶 、 copper(l) iodide 、 叠氮基三甲基硅烷 、 zinc trifluoromethanesulfonate 作用下， 以 二氯甲烷 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  循环次级叠氮化物的动力学拆分，使用对映选择性铜催化的叠氮化物-炔烃环加成反应。

  摘要：

  通过动力学拆分报道了对映选择性铜催化的叠氮化物-炔烃环加成反应（E-CuAAC）。以受限的炔烃（高达97：3对映体比率（er））高收率分离手性三唑。容许一定范围的底物（> 30个实施例），并且反应按比例缩放至> 1g。通过重结晶可以提高三唑产物的er值，并且可以将外消旋的叠氮化物外消旋和再循环。再循环叠氮化物允许有效使用不需要的叠氮化物对映异构体。

  DOI：

  10.1021/acs.orglett.9b01556
• 作为产物：
  描述：

  6-甲基-4-苯并二氢呋喃-4-酮 在 甲醇 、 sodium tetrahydroborate 作用下， 反应 2.0h， 以470 mg的产率得到(+/-)-6-Methyl-4-chromanol
  参考文献：
  名称：

  循环次级叠氮化物的动力学拆分，使用对映选择性铜催化的叠氮化物-炔烃环加成反应。

  摘要：

  通过动力学拆分报道了对映选择性铜催化的叠氮化物-炔烃环加成反应（E-CuAAC）。以受限的炔烃（高达97：3对映体比率（er））高收率分离手性三唑。容许一定范围的底物（> 30个实施例），并且反应按比例缩放至> 1g。通过重结晶可以提高三唑产物的er值，并且可以将外消旋的叠氮化物外消旋和再循环。再循环叠氮化物允许有效使用不需要的叠氮化物对映异构体。

  DOI：

  10.1021/acs.orglett.9b01556

文献信息

• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• BENZYL PIPERIDINE COMPOUND
  申请人：Toyoda Tomohiro

  公开号：US20120130077A1

  公开（公告）日：2012-05-24

  Provided is a new serotonin-reuptake inhibitor that exhibits affinity for serotonin-1A receptors. Said serotonin-reuptake inhibitor is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. In the formula, R 1 represents a hydrogen atom, a 2-hydroxyethyl group, or a 2-methoxyethyl group. R 2 represents one of the following bonded to a methylene group which is bonded to a piperidine ring: a chlorine atom bonded in a p-position; a bromine atom bonded in a p-position; a methyl group bonded in a p-position; a chlorine atom bonded in an m-position; or a bromine atom bonded in an m-position. Either Y 1 represents a hydrogen atom and Y 2 represents a hydrogen atom or a hydroxyl group, or Y 1 and Y 2 together represent an oxo group. Z represents a group represented by one of the following formulas: formula (3-1-1), formula (3-1-2), formula (3-2-1), formula (3-2-2), formula (3-3-1), formula (3-3-2), formula (3-4-1), or formula (3-4-2). However, if R 1 represents a 2-hydroxyethyl group or a 2-methoxyethyl group and Y 1 and Y 2 both simultaneously represent hydrogen atoms, then Z represents a group represented by one of the following formulas: formula (3-1-2), formula (3-2-1), formula (3-2-2), formula (3-3-1), formula (3-3-2), formula (3-4-1), or formula (3-4-2).

  提供一种新的血清素再摄取抑制剂，该抑制剂具有亲和力与血清素-1A受体结合。所述血清素再摄取抑制剂是由式（1）表示的化合物或其药理学可接受的盐。在该式中，R1代表氢原子、2-羟乙基基团或2-甲氧基乙基基团。R2代表以下之一，与连接到哌啶环的亚甲基团结合：连接在p-位置的氯原子；连接在p-位置的溴原子；连接在p-位置的甲基基团；连接在m-位置的氯原子；或连接在m-位置的溴原子。Y1代表氢原子，Y2代表氢原子或羟基，或Y1和Y2一起代表醛基。Z代表由以下任一式子表示的基团：式（3-1-1）、式（3-1-2）、式（3-2-1）、式（3-2-2）、式（3-3-1）、式（3-3-2）、式（3-4-1）或式（3-4-2）。然而，如果R1代表2-羟乙基基团或2-甲氧基乙基基团，并且Y1和Y2同时代表氢原子，则Z代表由以下任一式子表示的基团：式（3-1-2）、式（3-2-1）、式（3-2-2）、式（3-3-1）、式（3-3-2）、式（3-4-1）或式（3-4-2）。
• Ramadas; David Krupadanam, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1997, vol. 36, # 12, p. 1119 - 1122
  作者：Ramadas、David Krupadanam

  DOI：——

  日期：——
• Enantioselective reduction of 4-chromanone and its derivatives by selected filamentous fungi
  作者：Tomasz Janeczko、Jadwiga Dmochowska-Gładysz、Antoni Szumny、Edyta Kostrzewa-Susłow

  DOI：10.1016/j.molcatb.2013.09.004

  日期：2013.12

  Biotransformation of 4-chromanone and its derivatives in the cultures of three biocatalysts: Didymosphaeria igniaria, Colyneum betulinum and Chaetomium sp. is presented. The biocatalysts were chosen due to their capability of enantiospecific reduction of low-molecular-weight ketones (acetophenone and its derivatives and alpha- and beta-tetralone). The substrates were reduced to the respective S-alcohols with high enantiomeric excesses, according to the Prelog's rule. In the culture of Chaetomium sp. after longer biotransformation time an inversion of configuration of the formed alcohols was also observed. The highest yield of transformation was observed for 6-methyl-4-chromanone. In all the tested cultures, the higher was the molecular weight of a chromanone, the lower conversion percent was observed. (C) 2013 Elsevier B.V. All rights reserved.
• Enantioselective acylation of chroman-4-ols catalysed by lipase from Pseudomonas cepecia (Amano PS)
  作者：S Ramadas、G.L David Krupadanam

  DOI：10.1016/s0957-4166(97)00366-2

  日期：1997.9

  Lipase Amano PS catalysed acylation of (+/-)-chroman-4-ols using vinyl acetate as the acyl donor in n-hexane gave (R)-(+)-chroman-4-ol acetates and (S)-(-)-chroman-4-ols in high enantiomeric excess. The relationship between the position of the substituents in the chroman-4-ol to the ee and the spatial characteristics of the enzyme active site are proposed. (C) 1997 Elsevier Science Ltd.